IL17A and psoriasis: Specifically, HLA-Cw6, the primary psoriasis genetic susceptibility allele [19,20] and five variants in the protein-coding and untranslated regions of the IL-17A gene [21] have been tested for association with response to Secukinumab and Ixekinumab, with no positive results.